PCV chemotherapy for recurrent glioblastoma multiforme

被引：76

作者：

Kappelle, AC

Postma, TJ

Taphoorn, MJB

Groeneveld, GJ

van den Bent, MJ

van Groeningen, CJ

Zonnenberg, BA

Sneeuw, KCA

Heimans, JJ

机构：

[1] Vrije Univ Amsterdam, Univ Hosp, Dept Neurol, NL-1007 MB Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Univ Hosp, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands

[3] Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands

[4] Univ Utrecht, Med Ctr, Dept Med Oncol, Utrecht, Netherlands

[5] Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Neurooncol, Rotterdam, Netherlands

[6] Ctr Comprehens Canc, Amsterdam, Netherlands

来源：

NEUROLOGY | 2001年 / 56卷 / 01期

关键词：

D O I：

10.1212/WNL.56.1.118

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age <40 years and Karnofsky Performance Status <greater than or equal to>90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.

引用

页码：118 / 120

页数：3

共 11 条

[1] CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA
CAIRNCROSS, G
MACDONALD, D
LUDWIN, S
LEE, D
CASCINO, T
BUCKNER, J
FULTON, D
DROPCHO, E
STEWART, D
SCHOLD, C
WAINMAN, N
EISENHAUER, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2013 - 2021
[2] GUTIN PH, 1975, CANCER, V35, P1398, DOI 10.1002/1097-0142(197505)35:5<1398::AID-CNCR2820350524>3.0.CO
[3] 2-C
[4] LEVIN VA, 1980, CANCER TREAT REP, V64, P237
[5] PHASE-III COMPARISON OF BCNU AND THE COMBINATION OF PROCARBAZINE, CCNU, AND VINCRISTINE ADMINISTERED AFTER RADIOTHERAPY WITH HYDROXYUREA FOR MALIGNANT GLIOMAS
LEVIN, VA
WARA, WM
DAVIS, RL
VESTNYS, P
RESSER, KJ
YATSKO, K
NUTIK, S
GUTIN, PH
WILSON, CB
[J]. JOURNAL OF NEUROSURGERY, 1985, 63 (02) : 218 - 223
[6] RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA
MACDONALD, DR
CASCINO, TL
SCHOLD, SC
CAIRNCROSS, JG
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1277 - 1280
[7] Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma
Postma, TJ
van Groeningen, CJ
Witjes, RJGM
Weerts, JGE
Kralendonk, JH
Heimans, JJ
[J]. JOURNAL OF NEURO-ONCOLOGY, 1998, 38 (01) : 69 - 75
[8] SURVIVAL IN PATIENTS WITH RECURRENT GLIOMA AS A MEASURE OF TREATMENT EFFICACY - PROGNOSTIC FACTORS FOLLOWING NITROSOUREA CHEMOTHERAPY
RAJAN, B
ROSS, G
LIM, CC
ASHLEY, S
GOODE, D
TRAISH, D
BRADA, M
[J]. EUROPEAN JOURNAL OF CANCER, 1994, 30A (12) : 1809 - 1815
[9] Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
van den Bent, MJ
Kros, JM
Heimans, JJ
Pronk, LC
van Groeningen, CJ
Krouwer, HGJ
Taphoorn, MJB
Zonnenberg, BA
Tijssen, CC
Twijnstra, A
Punt, CJA
Boogerd, W
[J]. NEUROLOGY, 1998, 51 (04) : 1140 - 1145
[10] Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
Wong, ET
Hess, KR
Gleason, MJ
Jaeckle, KA
Kyritsis, AP
Prados, MD
Levin, VA
Yung, WKA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2572 - 2578

← 1 2 →